We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

166 hedge funds and large institutions have $801M invested in Ariad Pharmaceuticals Inc in 2013 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 51 increasing their positions, 58 reducing their positions, and 88 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

12% less repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 58

20% less funds holding

Funds holding: 208166 (-42)

26% less call options, than puts

Call options by funds: $35.5M | Put options by funds: $48.1M

48% less first-time investments, than exits

New positions opened: 46 | Existing positions closed: 88

72% less capital invested

Capital invested by funds: $2.85B → $801M (-$2.05B)

Holders
166
Holders Change
-42
Holders Change %
-20.19%
% of All Funds
4.82%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.12%
New
46
Increased
51
Reduced
58
Closed
88
Calls
$35.5M
Puts
$48.1M
Net Calls
-$12.6M
Net Calls Change
+$3.73M
Name Holding Trade Value Shares
Change
Change in
Stake
Axa
26
Axa
France
$6.59M +$2.08M +385,571 +66%
Goldman Sachs
27
Goldman Sachs
New York
$6.27M -$38.9M -7,203,784 -89%
Geode Capital Management
28
Geode Capital Management
Massachusetts
$5.88M +$327K +60,517 +8%
EEG
29
E.E. Geduld
$5.7M +$4.51M +835,100 New
Northern Trust
30
Northern Trust
Illinois
$5.4M +$68.8K +12,734 +2%
CM
31
Corvex Management
New York
$4.95M +$3.91M +725,000 New
Bank of New York Mellon
32
Bank of New York Mellon
New York
$4.87M -$470K -87,056 -11%
RPAM
33
Rhenman & Partners Asset Management
Sweden
$4.77M +$3.78M +700,000 New
RA
34
Royce & Associates
New York
$4.68M +$3.71M +686,602 New
IIM
35
Ironwood Investment Management
Massachusetts
$4.12M +$144K +26,754 +5%
BNP Paribas Asset Management
36
BNP Paribas Asset Management
France
$3.83M +$2.21M +408,704 +268%
Allianz Asset Management
37
Allianz Asset Management
Germany
$3.81M -$6.01M -1,113,500 -67%
GC
38
Guggenheim Capital
Illinois
$3.79M +$1.05M +194,559 +54%
VanEck Associates
39
VanEck Associates
New York
$3.4M +$325K +60,286 +14%
Dimensional Fund Advisors
40
Dimensional Fund Advisors
Texas
$3.28M -$126K -23,422 -5%
PPA
41
Parametric Portfolio Associates
Washington
$3.27M +$2.25M +416,935 +658%
SC
42
Selz Capital
New York
$2.73M +$2.16M +400,000 New
CS
43
Credit Suisse
Switzerland
$2.71M -$667K -123,482 -24%
California Public Employees Retirement System
44
California Public Employees Retirement System
California
$2.7M -$44.6K -8,256 -2%
Citadel Advisors
45
Citadel Advisors
Florida
$2.62M +$855K +158,426 +70%
Morgan Stanley
46
Morgan Stanley
New York
$2.37M -$3.6M -666,737 -66%
California State Teachers Retirement System (CalSTRS)
47
California State Teachers Retirement System (CalSTRS)
California
$2.28M +$11.9K +2,200 +0.7%
Charles Schwab
48
Charles Schwab
California
$2.23M +$163K +30,165 +10%
State Board of Administration of Florida Retirement System
49
State Board of Administration of Florida Retirement System
Florida
$2.17M
Deutsche Bank
50
Deutsche Bank
Germany
$2.02M -$8.15M -1,510,337 -84%

ARIA Hedge Fund Activity: Q4 2013 in Review

166 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q4 2013, worth a combined $801M — down 72% from $2.85B a quarter earlier.

Sellers outnumbered buyers: 88 funds closed out of ARIA and 46 opened new positions — a net loss of 42 holders — while 58 trimmed existing stakes and 51 added.

The largest buyer was Camber Capital Management, opening a new position worth an estimated $28.3M. The largest seller was Waddell & Reed Financial, exiting entirely with an estimated $106M sold.

  • 166 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q4 2013, down from 208 in Q3 2013.
  • Funds reported $801M of Ariad Pharmaceuticals Inc stock for Q4 2013, down 72% quarter-over-quarter.
  • 46 funds opened new Ariad Pharmaceuticals Inc positions in Q4 2013 and 88 closed out, a net change of -42 holders.
  • The largest Ariad Pharmaceuticals Inc buyer in Q4 2013 was Camber Capital Management, an estimated $28.3M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q4 2013 was Waddell & Reed Financial, an estimated $106M sold.

Based on aggregated 13F filings for Q4 2013.